Physician profile
Donna Davis
NPI 1902812910
$582.00
in general payments reported to CMS, 2019-2025
13 companies · $50.67 in 2025
The $50.67 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $47.52 · 2021: $146 · 2022: $70.19 · 2023: $74.24 · 2024: $85.04 · 2025: $50.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $209.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $143.79 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $83.00 | 2019 | |
| Lundbeck LLC | $72.63 | 2021 | |
| Collegium Pharmaceutical, INC. | $70.26 | 2024-2025 | Xtampza |
| Boston Scientific Corporation | $41.42 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Forte Bio-Pharma LLC | $33.18 | 2024 | Prolate, Nalocet |
| Protega Pharmaceutials INC | $32.94 | 2023 | Roxybond |
| Medtronic USA, INC. | $28.69 | 2020 | |
| Allergan, INC. | $18.83 | 2020 | |
| Averitas Pharma INC. | $17.72 | 2023 | Qutenza |
| Virtus Pharmaceuticals LLC | $14.43 | 2025 | Levorphanol Tartrate |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Glaxosmithkline, LLC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.